(Q33343008)

English

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

G Flux

3

0 references

object named as

G Cook

9

0 references

author name string

J M O'Sullivan

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

V R McCready

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A R Norman

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F M Buffa

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Chittenden

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Guy

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Pomeroy

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Gadd

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Treleaven

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Al-Deen

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Horwich

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R A Huddart

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D P Dearnaley

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

86

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1715-1720

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

1 June 2002

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

The challenge of locally advanced prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Peripheral blood stem cell transplantation: from laboratory to clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375418

21 June 2018

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600348

21 January 2018

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600348

21 January 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600348

21 January 2018

The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12087455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/12087455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12087455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/12087455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6600348

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33343008&oldid=2195263799"